[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

133

1 would its implications be.
2 Before you make too many assumptions that
3 it's not an issue, I would suggest you talk to the
4 plaintiffs' bar as well as the insurance companies.
5 I think the people, including myself, who would like
6 to get on with this, while we also deal with the
7 science issues, there are a few other policy issues
8 like these which need to be addressed now in order not
9 to hold up deliberations about the practicality of a
10 rapidly implemented large-scale simple trial.
11 DR. BROWN: There's another flip side of
12 that politically related issue. What happens to those
13 populations who were -- let's say we start up the
14 large, simple trial of a couple of candidates. A year
15 or two comes down the line. We get another candidate
16 that we find that there's greater scientific support
17 for.
18 Now, to recruit persons for that trial who
19 may want to leave the large, simple trial, what impact
20 will that have on accrual on this next candidate from
21 the standpoint of further vaccine development?
22 Additionally, suppose we do again find a
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]